Dr. Gerald Clarke was the first in the area to use this incredible game-changer for patients with open-angle glaucoma.
iStent inject® is used for the reduction of IOP (intraocular pressure) in adult patients with mild-to-moderate primary open-angle glaucoma.
iStent inject® creates two patent bypass pathways through the trabecular meshwork—the main source of resistance for aqueous outflow—resulting in multi-directional flow through Schlemm’s canal. And it is the smallest medical device known to be implanted in the human body. Together, these unique advantages are designed to provide exceptional results in a truly micro-invasive approach.
With iStent inject®, two multi-directional stents are placed two to three clock hours apart. Together, they are designed to deliver access to multiple collector channels and arcs of flow that can span five to six clock hours. iStent inject® may also re-establish flow in previously dormant outflow channels.
iStent inject® is proven to have an excellent safety profile, comparable to cataract surgery alone. It also offers much more:
- Micro-invasive and astigmatically-neutral
- Utilizes the conventional outflow pathway
- Leaves natural anatomy intact, preserving the potential for future treatment options, including drug delivery devices
- Minimally traumatic to delicate eye tissue and spares conjunctival tissue
- Reduces risk of hypotony by utilizing the natural episcleral venous pressure
- Offers postoperative care profile similar to cataract surgery